Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
for the initial treatment of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer patients failed to achieve its primary goals. Initial or first-line treatment refers to those patients who have previously not been treated for this indication. The phase II/III SKYSCRAPER-06 study evaluated Roche's combination therapy compared with Merck 's MRK Keytruda (pembrolizumab) and chemotherapy in 542 patients with the lung cancer indication. The study's primary endpoints comprised progression-free survival (PFS) and overall survival (OS). Roche's tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. The candidate's unique mechanism of action suppresses the immune response to cancer and acts as an immune amplifier when combined with othercancer immunotherapies, such as Tecentriq. The study results showed that the combination of tiragolumab plus Tecentriq and chemotherapy was less effective in PFS and OS compared with th
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Stock Market News for Oct 4, 2024 [Yahoo! Finance]Yahoo! Finance
- Should Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? [Yahoo! Finance]Yahoo! Finance
- Could Summit Therapeutics Become the Next Merck? [Yahoo! Finance]Yahoo! Finance
- U.S. In Vitro Fertilization Market Analysis Report 2024-2030: Societal Norms and Attitudes Shift, Driving IVF Demand [Yahoo! Finance]Yahoo! Finance
- ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 7/30/24 - Beat
MRK
Sec Filings
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- MRK's page on the SEC website